Marco Boorsma

Marco is a Partner at Forbion Capital Partners investing in Life Science companies. He serves on the Board of RSPR Pharma and is an observer to the Board of Exosome Diagnostics and Oxyrane. He previously served on the Board of Dezima Pharma (sold to Amgen). Before joining Forbion, Marco was Business Development Director at DSM Pharmaceutical Products. Prior to DSM, Marco was a project manager and scientist at vaccine company Cytos Biotechnology (Switzerland). After obtaining a Master’s degree in molecular biology from the University of Groningen in the Netherlands, Marco received his Ph.D. in biotechnology from the ETH Institute for Technology in Zürich, Switzerland, and worked at the MRC Laboratory for Molecular Biology in Cambridge, UK.